Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 8/20 | 0.43 |
| ▸ | PPARA | Q07869 | 8/20 | 0.43 |
| ▸ | ACACB | O00763 | 5/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622689 | 1.00 | LMNA (0.44) | LMNATSHRTDP1FFAR1PPARD | |
| SCHEMBL5521975 | 1.00 | LMNA (0.44) | LMNATSHRTDP1FFAR1PPARD | |
| SCHEMBL6676937 | 0.85 | MAPT (0.42) | LMNATSHRTDP1PPARDPPARA | |
| SCHEMBL6676945 | 0.85 | MAPT (0.42) | LMNATSHRTDP1PPARDPPARA | |
| SCHEMBL14427083 | 0.85 | FFAR1 (0.47) | LMNATSHRFFAR1 | |
| SCHEMBL14427110 | 0.83 | LMNA (0.48) | LMNATSHRTDP1FFAR1PPARD | |
| SCHEMBL14427107 | 0.83 | PPARD (0.52) | LMNATSHRTDP1FFAR1PPARD | |
| SCHEMBL29485563 | 0.82 | TDP1 (0.61) | TDP1PPARDPPARAACACB | |
| SCHEMBL1610078 | 0.81 | TDP1 (0.48) | LMNATSHRTDP1FFAR1PPARD | |
| SCHEMBL13937524 | 0.81 | KLK5 (0.41) | PPARAS1PR1S1PR3KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070105892-A1 | Amidino compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1761485-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2006-11-23 | — | — | US | disclosed |
| EP-1697355-A2 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063742-A2 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | LMNA 1267/4885TSHR 4193/4885TDP1 3821/4885 |
| US-20070105892-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | LMNA 1267/4885TSHR 4193/4885TDP1 3821/4885 |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | LMNA 2126/4885TSHR 4517/4885TDP1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.